Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada.
Anticancer Agents Med Chem. 2012 Feb;12(2):137-43. doi: 10.2174/187152012799014922.
Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.
双膦酸盐类药物是治疗晚期实体瘤骨转移患者的标准治疗方法。唑来膦酸在这一领域表现出最广泛的活性，除了乳腺癌和多发性骨髓瘤之外，还被批准用于预防各种实体瘤骨转移引起的骨骼相关事件。正在进行的研究评估了在这些情况下研究性药物的抗吸收潜力。大量的临床前证据和最近的临床进展支持这样一种假设，即唑来膦酸在某些情况下可以发挥有临床意义的抗癌活性，从而改善疾病结局和生存。这些数据在乳腺癌和多发性骨髓瘤中尤为有力，并在其他癌症治疗中也逐渐显现。本文将讨论在肺癌和除乳腺和泌尿生殖系统恶性肿瘤以外的实体瘤背景下，双膦酸盐类药物具有抗癌作用的新数据。
